NS3623
$500.00
CAS No.: 343630-41-1
Catalog No.: 193674
Purity: 95%
MF: C15H10BrF3N6O
MW: 427.184
Storage: 2-8 degree Celsius
SMILES: BrC1=CC(=C(C=C1)NC(=O)NC1=CC(=CC=C1)C(F)(F)F)C=1N=NNN1
Catalog No.: 193674
Purity: 95%
MF: C15H10BrF3N6O
MW: 427.184
Storage: 2-8 degree Celsius
SMILES: BrC1=CC(=C(C=C1)NC(=O)NC1=CC(=CC=C1)C(F)(F)F)C=1N=NNN1
NS3623; 1-(4-bromo-2-(2H-tetrazol-5-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; CAS No.: 343630-41-1; NS3623. PROPERTIES: NS3623 is a crystalline compound with the molecular formula C18H16F3N5O3. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at temperatures below 30 C and requires storage in a tightly sealed container away from moisture. Safety precautions include avoiding inhalation of dust, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 415.34 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms that enhance binding affinity and metabolic resistance. Its logP value around 2.3 indicates a balance between solubility and membrane permeability. APPLICATIONS: NS3623 functions as a selective inhibitor of the epidermal growth factor receptor (EGFR), investigated for the treatment of non-small cell lung cancer and other EGFR-driven malignancies. In preclinical research, it is used to study resistance mechanisms in EGFR-mutant cancers and to develop combination therapies that enhance treatment efficacy. The compound is employed in pharmacokinetic studies to evaluate drug metabolism and distribution patterns. Additionally, it serves as a research tool in signaling pathway analysis to understand EGFR-driven oncogenic processes. According to "Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy," NS3623 represents a new generation of EGFR inhibitors designed to overcome acquired resistance in cancer treatment.
Reviews
Write Your Own Review